PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways

Pharmacology Research and Perspectives

Volumn 2, Issue 4, 2014, Pages

  Megens, Anton A H P ^a   Hendrickx, Herman M R ^a   Mahieu, Michel M A ^a   Wellens, Annemie L Y ^a   de Boer, Peter ^a   Vanhoof, Greet ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Catalepsy; D1 antagonists; D1 receptors; D2 antagonists; D2 receptors; dopamine; dopamine depletion; dopamine modulators; locomotion; PDE10A

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; RESERPINE; UNCLASSIFIED DRUG;

AGITATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; ED50; EXPERIMENTAL HYPOACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84939183762     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.57     Document Type: Article

References (56)

1. Agid O, Kapur S, Remington G (2008). Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 13: 479–495.
2. Beutler LR, Wanat MJ, Quintana A, Sanz E, Bamford NS, Zweifel LS, et al. (2011). Balanced NMDA receptor activity in dopamine D1 receptor (D1R)- and D2R-expressing medium spiny neurons is required for amphetamine sensitization. Proc. Natl. Acad. Sci. USA 108: 4206–4211.
3. Bourne JA (2001). SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev 7: 399–414.
4. Colzi A, D'Agostini F, Cesura AM, Borroni E, Da Prada M (1993). Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J Pharmacol Exp Ther 265: 103–111.
5. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, et al. (2006). Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54: 1205–1213.
6. Dedeurwaerdere S, Wintmolders C, Vanhoof G, Langlois X (2011). Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker. J Pharmacol Exp Ther 339: 210–217.
7. Delong MR, Wichmann T (2007). Circuits and circuit disorders of the basal ganglia. Arch Neurol 64: 20–24.
8. DeMartinis N, Banerjee A, Kumar V, Boyer S, Schmidt C, Arroyo S (2012). Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia. Schizophr Res 136(Suppl. 1): S262.
9. Desai RI, Terry P, Katz JL (2005). A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacol Biochem Behav 81: 843–848.
10. Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, Love PE, et al. (1994). Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl. Acad. Sci. USA 91: 12564–12568.
11. Filinger EJ (1994). Effect of a reserpine-like agent on the release and metabolism of [3H]NA in cell bodies and terminals. Gen Pharmacol 25: 1039–1043.
12. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, et al. (1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274: 18438–18445.
13. Gerfen CR (2000). Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23: S64–S70.
14. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22: 5042–5054.
15. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, et al. (2009). Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331: 574–590.
16. Graybiel AM (1990). Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13: 244–254.
17. Graybiel AM (2000). The basal ganglia. Curr Biol 10: R509–R511.
18. Gresack JE, Seymour PA, Schmidt CJ, Risbrough VB (2013). Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacology 231: 2189–2197.
19. Hillegaart V, Ahlenius S, Magnusson O, Fowler CJ (1987). Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response. Pharmacol Biochem Behav 27: 159–164.
20. Hirschfeld RM (2000). History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 61(Suppl 6): 4–6.
21. Hurley MJ, Jenner P (2006). What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 111: 715–728.
22. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081–1090.
23. Kehler J, Kilburn JP (2009). Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin Ther Pat 19: 1715–1725.
24. Kehler J, Nielsen J (2011). PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 17: 137–150.
25. Kehler J, Ritzen A, Greve DR (2007). The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Pat 17: 147–158.
26. Langlois X, Megens A, Lavreysen H, Atack J, Cik M, te Riele P, et al. (2012). Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 342: 91–105.
27. Lewi PJ, Niemegeers CJE, Gypen LMJ (1977). First hand estimation of the median effective dose (ED50) and its confidence interval, assuming a linear log dose-response function. Department of Global Medical and Scientific Information, Johnson & Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica, Beerse, Belgium. Internal Report N123705/1.
28. Leysen JE (2000). Receptor profile of neuroleptics. Pp. 57–81. in BA Ellenbroek and AR Cools, eds. Atypical antipychotics. Birkhauser Verlag, Basel, Switzerland.
29. Leysen JE, Niemegeers CJE (1985). Neuroleptics. Pp. 331–361 in A Lajtha, ed. Handbook of neurochemistry. Vol. 9. Plenum Publishing Corporation, New York, NY.
30. Lobo MK, Covington HE, III, Chaudhury D, Friedman AK, Sun H, Damez-Werno D, et al. (2010). Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 330: 385–390.
31. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999). Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 234: 109–117.
32. Mailman R, Huang X, Nichols DE (2001). Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs 2: 1582–1591.
33. Megens AAHP, Hendrickx HMR, Hens KA, Fonteyn I, Langlois X, Lenaerts I, et al. (2014). Pharmacology of JNJ42314415, a centrally active PDE10A inhibitor. A comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotics. J Pharmacol Exp Ther 349: 1–14.
34. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ (2007). Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8: 54–59.
35. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, et al. (2008). Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28: 10460–10471.
36. Nishi A, Kuroiwa M, Shuto T (2011). Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons. Front Neuroanat 5: 43.
37. Rodefer JS, Murphy ER, Baxter MG (2005). PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21: 1070–1076.
38. Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008). Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 105: 546–556.
39. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, et al. (2008). Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325: 681–690.
40. Schotte A, Leysen JE (1998). Receptor binding profile of risperidone. Acta Psychiatr Belg 98: 64–75.
41. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, et al. (2003). Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985: 113–126.
42. Siuciak JA (2008). The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22: 983–993.
43. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, et al. (2006). Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51: 386–396.
44. Soderling SH, Bayuga SJ, Beavo JA (1999). Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA 96: 7071–7076.
45. Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J (2009). Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to d-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109: 766–775.
46. Stanley ME, Glick SD (1976). Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology 15: 393–394.
47. Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ (2010). Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology 58: 444–451.
48. Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30: 228–235.
49. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR (2009). Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation. J Pharmacol Exp Ther 328: 785–795.
50. Tsutakawa RK (1982). Statistical methods in bioassay. Pp. 236–243 in S Kotz and NL Johnson, eds. Estimation of relative potency from quantal responses. Encyclopedia of statistical science, Vol. 1. J. Wiley, New York, NY.
51. Vanhoof G, Megens A, Ver Donck L, Langlois X, Mahieu M, Daems H, et al. (2012). PDE10 inhibitors as neuromodulators. Abstract 42nd Annual Meeting of the Society of Neuroscience, October 13–17, New Orleans, LA.
52. Wall VZ, Parker JG, Fadok JP, Darvas M, Zweifel L, Palmiter RD (2011). A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling. Mol Cell Neurosci 46: 21–31.
53. Wang JQ, McGinty JF (1997). The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J Pharmacol Exp Ther 281: 972–982.
54. Westfall TC, Westfall DP (2005). Adrenergic agonists and antagonists. Pp. 237–295 in LL Brunton, JS Lazo and KL Parker, eds. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill Medical Publishing Division, New York, NY.
55. Wilson CJ (2014). Basal Ganglia. Oxford Univ. Press, Oxford, U.K.
56. Xu M, Hu XT, Cooper DC, Moratalla R, Graybiel AM, White FJ, et al. (1994). Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79: 945–955.